Groundbreaking Results for Carrelizumab in Late-Stage Esophageal Squamous Cell Carcinoma
05 Jun 2024
Clinical ResultDrug ApprovalASCOImmunotherapy
In a major update presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the final analysis of the ESCORT-1st study revealed exceptional long-term outcomes for patients with advanced esophageal squamous cell carcinoma (ESCC) treated with the immunotherapy carrelizumab in combination with chemotherapy.
The study, led by Professor Ruihua Xu from the Sun Yat-sen University Cancer CenterCancer Center, showed that the carrelizumab plus chemotherapy regimen significantly improved overall survival (OS) and progression-free survival (PFS) compared to placebo plus chemotherapy. Remarkably, the 3-year overall survival rate reached an impressive 25.6% in the carrelizumab arm, meaning that approximately one in four patients with late-stage ESCC lived beyond 3 years.
"These updated results from the ESCORT-1st study are truly groundbreaking," said Dr. Emily Sharma, a leading oncologist. "It's really impressive that the survival rate for advanced esophageal cancer has gone up to over 25% in 3 years. This is a big step forward in treating such a tough disease."
The study also found that the clinical benefits of the carrelizumab-based regimen were consistent across different levels of PD-L1 expression, underscoring the broad applicability of this treatment approach.
The ESCORT-1st study has become a game-changer in the way we manage esophageal squamous cell carcinoma," said Dr. Michael Watkins, an internationally renowned expert in gastrointestinal oncology.
"These data provide strong evidence supporting the use of carrelizumab in combination with chemotherapy as a new standard of care for patients with advanced ESCC."
Based on the impressive results from the ESCORT-1st study, the carrelizumab plus chemotherapy regimen was approved by China's National Medical Products Administration (NMPA) in December 2021 for the first-line treatment of unresectable locally advanced, recurrent, or metastatic ESCC. This landmark approval has the potential to bring renewed hope and improved outcomes to a significant number of patients facing this devastating disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.